| ticagrelor / Generic mfg. |
2014-004298-18: Ticagrelor versus clopidogrel in patients treated with drug eluting stent implantation for peripheral arterial disease Ticagrelor vs clopidogrel nei pazienti sottoposti ad impianto di stent a rilascio di paclitaxel nel distretto femoropopliteo: uno studio pilota, randomizzato, nidificato |
|
|
| Ongoing | 3 | 40 | Europe | Ticagrelor, Tablet, Brilique | AUSL 8, AstraZeneca S.p.a. | peripheral arterial disease arteriopatia obliterante periferica, obstructive atherosclerosis of leg arteries aterosclerosi ostruttiva delle arterie degli arti inferiori, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2013-003519-23: A Study Comparing Cardiovascular Effects of Ticagrelor versus Placebo in Patients with Type 2 Diabetes Mellitus |
|
|
| Ongoing | 3 | 650 | Europe | Ticagrelor 60mg film-coated tablets, BRILIQUE, BRILIQUE | AstraZeneca AB, AstraZeneca AB | major cardiovascular events in type 2 diabetes mellitus patients | | | | |
2013-001794-24: Effect of the therapy with Prasugrel or Ticagrelor in diabetic patients with acute cardiovascular diseases. Effetti della terapia con Prasugrel o Ticagrelor in pazienti diabetici con malattie acute cardiovascolari. |
|
|
| Ongoing | 3 | 42 | Europe | Prasugrel, Ticagrelor, EFIENT, BRILIQUE, EFIENT, BRILIQUE | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | Patients with Acute Coronary Syndrome and Diabetes Mellitus Pazienti con sindrome coronarica acuta e diabete mellito | | | | |
2015-005071-25: Comparison of different oral platelet function inhibitor treatment strategies for transitioning from the intravenous platelet function inhibitor cangrelor in patients undergoing elective percutaneous coronary interventions with coronary stent implantation |
|
|
| Ongoing | 3 | 110 | Europe | Film-coated tablet, Efient, Brilique, Plavix | University Heart Center Freiburg - Bad Krozingen, University Heart Center Freiburg - Bad Krozingen, Department of Cardiology and Angiology II | Patients with obstructive coronary heart disease undergoingpercutaneous coronary stent implantation., Patients with a significant narrowing of at least one coronary vessel and implantation of a coronary stent., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-002586-64: A randomized, pharmacodynamic study of cangrelor administration in STEMI patients loaded with ticagrelor Σε ασθενείς με οξύ έμφραγμα του μυοκαρδίου με ανάσπαση του διαστήματος ST που έχουν λάβει φόρτιση με τικαγκρελόρη, μετρούμε την αντιδραστικότητα των αιμοπεταλίων μετά από χορήγηση καγκρελόρης και τη συγκρίνουμε με την ομάδα ελέγχου (χωρίς κανγκρελόρη) |
|
|
| Ongoing | 3 | 30 | Europe | Ticagrelor, Powder for concentrate for solution for injection/infusion, Tablet, Kengrexal, Brilique | ELKE University of Athens, ELKE University of Athens | In the present study, in STEMI patients undergoing primary PCI we aim therefore to compare platelet inhibition achieved in patients loaded with ticagrelor followed by cangrelor (bolus plus infusion) vs ticagrelor alone loaded patients. Στην παρούσα μελέτη σε ασθενείς με STEMI που υποβάλλονται σε πρωτογενή αγγειοπλαστική, έχουμε ως στόχο να συγκρίνουμε την αναστολή των αιμοπεταλίων που επιτυγχάνεται από την χορήγηση της κανγκρελόρης (δόση εφόδου και στάγδην έγχυση) σε ασθενείς που έλαβαν φόρτιση με τικαγκρελόρη στην πρώτη ιατρική επαφή έναντι της χορήγησης τικαγρελόρης μόνο, χορηγούμενη επίσης στην πρώτη επαφή με ιατρό., STEMI patients undergoing primary PCI we aim therefore to compare platelet inhibition achieved in patients loaded with ticagrelor followed by cangrelor vs ticagrelor alone loaded patients. Ασθενείς με STEMI και αγγειοπλαστική συγκρίνουμε την αναστολή των αιμοπεταλίων από την χορήγηση της κανγκρελόρης σε ασθενείς που έλαβαν φόρτιση με τικαγκρελόρη έναντι της χορήγησης τικαγρελόρης μόνο, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-001754-33: Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgery Studio prospettico randomizzato per valutare l’effetto della doppia terapia antiaggregante piastrinica in pazienti sottoposti a bypass aortocoronarico con rivascolarizzazione miocardica incompleta |
|
|
| Ongoing | 3 | 800 | Europe | CARDIOASPIRINA, Film-coated tablet, Gastro-resistant tablet, BRILIQUE - 90 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER(PVC/PVDC/ALU) 60 COMPRESSE, CARDIOASPIRIN - 100 MG COMPRESSE GASTRORESISTENTI30 COMPRESSE | UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA, Università Campus Bio-Medico di Roma | in patients with Incomplete Revascularization after Coronary artery bypass graft surgery valutare l'effetto della doppia terapia antiaggregante piastrinica in pazienti sottoposti a bypass aortocoronarico con rivascolarizzazione miocardica incompleta., Incomplete Revascularization after Coronary artery bypass graft surgery bypass aortocoronarico con rivascolarizzazione miocardica incompleta., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2014-002142-50: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. Een gerandomiseerd, dubbel-blind, placebo-gecontroleerd onderzoek naar het effect van ticagrelor op de doorgankelijkheid van veneuze omleidingen in patiënten die coronaire bypass chirurgie ondergaan. |
|
|
| Not yet recruiting | 3 | 720 | Europe | Tablet, Brillique | St. Antonius Hospital, AstraZeneca, Stichting St. Antonius Hartennzorg | Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. Coronaire bypass operatie met gebruik van een of meerdere venengrafts., Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts. Coronaire bypass operatie met gebruik van een of meerdere venengrafts., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2015-000850-39: Assessment of Loading with the P2Y12 inhibitor Ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting: the ALPHEUS study. Randomizovaná, otevřená studie zhodnocující podání inhibitoru P2Y12 ticagreloru nebo clopidogrelu ke zmírnění ischemických příhod u pacientů určených k zavedení koronárního stentu. |
|
|
| Not yet recruiting | 3 | 1900 | RoW | Brilique, clopidogrel 75 mg, AZD6140, Coated tablet, Brilique, Trombex 75 mg potahované tablety | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), ASTRAZENECA, APHP | PCI-related myocardial infarction (MI type 4) or injury (I) within 48 hours (or at hospital discharge if earlier than 48 hours) of elective PCI/stent, PCI-related myocardial infarction (MI type 4) or injury (I) within 48 hours (or at hospital discharge if earlier than 48 hours) of elective PCI/stent, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2019-002391-13: Platelet inhibition with Ticagrelor 60 mg versus Ticagrelor 90 mg twice daily in elderly patients with acute coronary syndrome (ACS). Inibizione dell'aggregazione piastrinica con Ticagrelor 60 mg versus Ticagrelor 90 mg BID in pazienti anziani con sindrome coronarica acuta (SCA). |
|
|
| Not yet recruiting | 3 | 50 | Europe | TICAGRELOR 90 mg, ticagrelor 60 MG, Cardioaspirin 100 mg compresse gastroresistenti, [TICAGRELOR 90 mg], [ticagrelor 60 MG], [024840074], Film-coated tablet, Gastro-resistant tablet, BRILIQUE 90 MG COMPRESSE RIVESTITE CON FILM, BRILIQUE 60 MG COMPRESSE RIVESTITE CON FILM, Cardioaspirin 100 mg Compresse gastroresistenti | AOU FEDERICO II | Acute coronary syndrome Sindrome coronarica acuta, Acute coronary syndrome Sindrome coronarica acuta, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04754789: Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI |
|
|
| Not yet recruiting | 3 | 160 | NA | Atorvastatin, aspirin, ticagrelor, Aspirin | Assiut University | ST Elevation Myocardial Infarction | 03/21 | 03/21 | | |
2020-004887-24: Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI) |
|
|
| Not yet recruiting | 3 | 2230 | Europe | Brilique 60 mg, Brilique 90 mg, Coated tablet, Brilique 60 mg, Brilique 90 mg | Marcin Gruchała Medical University of Gdańsk, Medical Research Agency | Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04952311: Efficacy Study of Clopidogrel in High-risk Population With Acute Non-disabling Cerebrovascular Events â…¡ |
|
|
| Recruiting | 3 | 10878 | RoW | Tagrelor combined with aspirin, Clopidogrel combined with aspirin | Peking University Third Hospital, Beijing Tiantan Hospital | Acute Nondisabling Ischemic Stroke, Transient Ischemic Attack | 06/21 | 09/21 | | |
| Recruiting | 3 | 800 | Europe | Ticagrelor, Brilique, acetylsalicylic acid | Campus Bio-Medico University | Coronary Artery Disease | 08/21 | 12/26 | | |
2020-005130-15: Evaluation of safety i efficacy de-escalation antiplatelet strategies in acute coronary syndrome. Ocena bezpieczeństwa i skuteczności dwóch opartych na tikagrelorze strategii deeskalacji leczenia przeciwpłytkowego w ostrym zespole wieńcowym. |
|
|
| Not yet recruiting | 3 | 4500 | Europe | Coated tablet, Aspirin Cardio 100mg, Briliaque 60mg, Briliaque 90mg | Nicolaus Copernicus University in Torun, Medical Research Agency | Acute Coronary Syndrom (ACS), A range of conditions associated with sudden, reduced blood flow to the heart., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT06591377: Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Cilostazol 100 MG, group B | Kafrelsheikh University | Ischemic Stroke | 09/24 | 10/24 | | |
NCT06591390: Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Cilostazol 100 MG, group B | Kafrelsheikh University | Ischemic Stroke | 09/24 | 10/24 | | |
NCT06591338: Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Clopidogrel, group B | Kafrelsheikh University | Ischemic Stroke | 09/24 | 09/24 | | |
NCT06591312: Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Clopidogrel, group B | Kafrelsheikh University | Ischemic Stroke | 09/24 | 09/24 | | |
2022-001838-11: Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis.“Reducing inflammation in ischemic stroke with colchicine (riisc), and ticagrelor in high-risk patients-extended treatment in ischemic stroke (thetis”) ÉVALUATION D’UNE FAIBLE DOSE DE COLCHICINE ET DE TICAGRELOR EN PREVENTION D’UNE RECIDIVE D’INFARCTUS CEREBRAL CHEZ DES PATIENTS QUI ONT EU UN INFARCTUS CEREBRAL OU UN ACCIDENT ISCHEMIQUE CEREBRAL TRANSITOIRE D’ORIGINE ATHEROSCLEREUSE |
|
|
| Not yet recruiting | 3 | | Europe | Ticagrelor, Colchicine, Acide acétylsalicylique, KARDEGIC, Tablet, Powder for oral suspension, BRILIQUE 90 mg, COLCHICINE OPOCALCIUM 1 mg, Acide Acétylsalicylique 100 mg, Acide Acétylsalicylique | APHP DRCI | Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis ÉVALUATION D’UNE FAIBLE DOSE DE COLCHICINE ET DE TICAGRELOR EN PREVENTION D’UNE RECIDIVE D’INFARCTUS CEREBRAL CHEZ DES PATIENTS QUI ONT EU UN INFARCTUS CEREBRAL OU UN ACCIDENT ISCHEMIQUE CEREBRAL TRANSITOIRE D’ORIGINE ATHEROSCLEREUSE, Evaluation of low dose colchicine and ticagrelor in prevention of ischemic stroke in patients with stroke due to atherosclerosis ÉVALUER UNE FAIBLE DOSE DE COLCHICINE ET TICAGRELOR:PREVENTION D’UNE RECIDIVE D’INFARCTUS CEREBRAL CHEZ DES PATIENTS QUI ONT EU UN INFARCTUS CEREBRAL OU UN ACCIDENT ISCHEMIQUE CEREBRAL ATHEROSCLEREUSE | | | | |
Tip-HAT, NCT04946929: Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT) |
|
|
| Not yet recruiting | 3 | 50 | RoW | Ticagrelor Oral Tablet [Brilinta], Ticagrelor, Low molecular weight heparin | RenJi Hospital | Hepatic Artery Thrombosis, Liver Transplant; Complications, Pediatric Disease | 12/22 | 03/23 | | |
TROUPER, NCT03357874: TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome. |
|
|
| Recruiting | 3 | 514 | Europe | Clopidogrel, Ticagrelor | Assistance Publique Hopitaux De Marseille | Acute Coronary Syndrome | 01/23 | 08/23 | | |
2021-003906-34: Cardiovascular and bleeding outcomes after the implantation of a drug-eluting stent plus a short antiplatelet therapy: ANGIODAPT trial. Resultados cardiovasculares y hemorrágicos tras las la implantación de un stent liberador de fármacos y un tratamiento antiplaquetario de corta duración: ensayo ANGIODAPT. |
|
|
| Not yet recruiting | 3 | 2312 | Europe | clopidogrel, prasugrel, ticagrelor, acetylsalicylic acid, Film-coated tablet, Chewable tablet | iVascular, S.L.U., iVascular, S.L.U. | Coronary artery disease Enfermedad arterial coronaria, Coronary artery disease (including stable angina and heart attack) Enfermedad arterial coronaria (incluyendo angina de pecho estable y ataque al corazón), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2023-000029-10: Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleeding Riduzione anticipata della terapia antiaggregante in pazienti con Sindrome Coronarica Acuta trattata con impianto di stent e ad elevato rischio di sanguinamento |
|
|
| Not yet recruiting | 3 | 200 | Europe | Brilique, prasugrel, Clopidogrel, [Ticagrelor], [prasugrel], [clopidogrel], [ticagrelor], Film-coated tablet, brilique, Brilique | Azienda Ospedaliera Universitaria Gaetano Martino Messina, Ministero della salute - Bando della ricerca finalizzata 2021 - grant GR-2021-12374500 | High bleeding risk (HBR) patients with a recent acute coronary syndrome (ACS ) who have undergone percutaneous coronary intervention (PCI) and are on double antiplatelet therapy (DAPT) Pazienti ad alto rischio di sanguinamento (HBR) con sindrome coronarica acuta (SCA) recente trattata con rivascolarizzazione coronarico per via percutanea (PCI) e in trattamento con doppia antiaggregazione (DAPT), acute cardiac ischemia ischemia acuta del miocardio, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-003621-36: Evaluation de la reperfusion myocardique et de la masse thrombotique endocoronaire après angioplastie primaire pour infarctus du myocarde sous cangrelor en intraveineux en plus du ticagrelor per os comparé au ticagrelor per os seul en cas de réactivité plaquettaire élevée. Evaluation de la reperfusion myocardique et de la masse thrombotique endocoronaire après angioplastie primaire pour infarctus du myocarde sous cangrelor en intraveineux en plus du ticagrelor per os comparé au ticagrelor per os seul en cas de réactivité plaquettaire élevée. |
|
|
| Not yet recruiting | 3 | 120 | Europe | Cangrelor, Powder for injection, Kengrexal | CHU CAEN Normandie, CHU CAEN Normandie | Patients admis pour angioplastie coronaire primaire (PPCI) pour infarctus du myocarde avec sus-décalage du segment ST (IDM ST+) Patients admis pour angioplastie coronaire primaire (PPCI) pour infarctus du myocarde avec sus-décalage du segment ST (IDM ST+), Patients admis pour angioplastie coronaire primaire (PPCI) pour infarctus du myocarde avec sus-décalage du segment ST (IDM ST+) Patients admis pour angioplastie coronaire primaire (PPCI) pour infarctus du myocarde avec sus-décalage du segment ST (IDM ST+), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT05553613: Ticagrelor Versus Clopidogrel in Ischemic Stroke |
|
|
| Completed | 3 | 900 | RoW | Ticagrelor 90 MG Oral Tablet, group A, Clopidogrel tablet, group B | Kafrelsheikh University | Ischemic Stroke | 10/23 | 01/24 | | |
NCT06120725: Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke |
|
|
| Completed | 3 | 580 | RoW | Ticagrelor 90 MG, group A, Clopidogrel, group B | Kafrelsheikh University | Ischemic Stroke | 09/23 | 11/23 | | |
| Completed | 3 | 90 | RoW | Ticagrelor 90mg, Ticer, Clopidogrel 75 mg, Osvix | Mazandaran University of Medical Sciences | Ischemic Stroke, Transient Ischemic Attack | 10/23 | 10/23 | | |
CAPITALPCIAF, NCT03331484: The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention |
|
|
| Active, not recruiting | 3 | 40 | Canada | Ticagrelor, Rivaroxaban | Ottawa Heart Institute Research Corporation | Atrial Fibrillation, Acute Coronary Syndrome | 11/23 | 12/23 | | |
NCT06196047: Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Cilostazol 100 MG, group B | Kafrelsheikh University | Ischemic Stroke | 12/24 | 12/24 | | |
| Recruiting | 3 | 200 | Europe, Canada, US, RoW | Bentracimab (PB2452) Infusion | SFJ Pharmaceuticals, Inc. | Hemorrhage, Urgent Surgery, Invasive Procedure | 01/25 | 01/25 | | |
| Recruiting | 3 | 2200 | RoW | Ticagrelor 90 MG, antiplatelet, Clopidogrel | National Institute of Cardiovascular Diseases, Pakistan, PharmEvo Pvt Ltd | Stent Thrombosis, Myocardial Infarction, Acute | 11/24 | 12/24 | | |
NCT06202755: Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke |
|
|
| Recruiting | 3 | 580 | RoW | Ticagrelor 90 MG, group A, Cilostazol 100 MG, group B | Kafrelsheikh University | Ischemic Stroke | 06/25 | 07/25 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
ELECTRA-SIRIO, NCT04718025: Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome |
|
|
| Recruiting | 3 | 4500 | Europe | Ticagrelor 90mg, Brilique, Ticagrelor 60mg, Aspirin, acetylsalicylic acid | Collegium Medicum w Bydgoszczy, Medical Research Agency, Poland | STEMI, NSTEMI, Unstable Angina | 06/24 | 06/24 | | |
NCT06561867: Ticagrelor Versus Cilostazol in Ischemic Stroke |
|
|
| Recruiting | 3 | 900 | RoW | Ticagrelor 90 MG, group A, Cilostazol 100 MG, group B | Kafrelsheikh University | Ischemic Stroke | 11/25 | 12/25 | | |
NCT04007055: The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions |
|
|
| Recruiting | 3 | 296 | US | Point of care screening for HPR, Ticagrelor 90mg | Marissa Jarosinski | Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease | 12/24 | 12/25 | | |
| Not yet recruiting | 3 | 50 | Europe | De-escalation to ticagrelor 60 mg at day 30, De-escalation to prasugrel 5 mg at day 30, Switch to ticagrelor 60 mg at day 45, Switch to prasugrel 5 mg at day 45 | Collegium Medicum w Bydgoszczy | Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina | 12/24 | 12/24 | | |
PICASSO, NCT05611242: Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial |
|
|
| Recruiting | 3 | 404 | US | MT+CAS with IV-AP, Thrombectomy, MT+CAS with PO-AP, MT+CAT with PO-AP | Mercy Health Ohio | Acute Ischemic Stroke | 03/26 | 05/27 | | |
| Recruiting | 3 | 20000 | Europe, Canada, Japan, US, RoW | Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir | UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore | Community-acquired Pneumonia, Influenza, COVID-19 | 02/26 | 02/28 | | |
| Not yet recruiting | 3 | 700 | Europe, Canada, US | Ticagrelor 90 MG, Ticagrelor placebo | Weill Medical College of Cornell University, Canadian Institutes of Health Research (CIHR) | Chronic Coronary Disease | 01/27 | 01/31 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
RIISC-THETIS, NCT05476991: Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis |
|
|
| Recruiting | 3 | 2800 | Europe | Colchicine 0.5 MG, Ticagrelor 90mg, Brilinta, Aspirin 75-300mg, Acetylsalicylic acid | Assistance Publique - Hôpitaux de Paris | Stroke, Stroke, Ischemic, Atherosclerosis, Myocardial Infarction, Coronary Syndrome, TIA, Cardiac Disease, Cerebral Infarction | 09/27 | 09/27 | | |
